Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin in advanced solid tumors
NCT02454972Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Aug 2015
- Primary completion
- Sep 2020
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 9
01
Overview
A Phase 2 trial of lurbinectedin in small cell lung cancer (SCLC), head and neck carcinoma (HNC), Neuroendocrine Neoplasm (NEN), biliary tract carcinoma (BTC), endometrial carcinoma, sponsored by PharmaMar. Started Aug 2015; status: completed.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)head and neck carcinoma (HNC)Neuroendocrine Neoplasm (NEN)biliary tract carcinoma (BTC)endometrial carcinoma
Beyond the preview
Go deeper on NCT02454972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454972.